ReadyRx review

ReadyRx makes one disclosure unusually well: it names the batch tests its compounded medications undergo — potency, sterility, pH and endotoxin — which are precisely the four metrics that matter for a sterile injectable, and it displays a LegitScript badge linked to the public checker. Its pricing is fully laid out, with a vial size and a monthly-versus-quarterly table on each product, but every headline is a first-month figure on a quarterly plan paid up front. Sermorelin's "from $155" becomes $185 a month from month two on that plan, and $225 a month if you pay monthly. Budget against those, not the headline.

ReadyRx is a US telehealth service organized by category: Metabolic health (compounded semaglutide, compounded tirzepatide, glutathione injection, glutathione nasal spray, metformin), Hormone health (sermorelin injection and sermorelin orally disintegrating tablets), and Energy and Recovery (NAD⁺ injection, NAD⁺ nasal spray, MIC+B12). Brand Ozempic and Zepbound pages exist alongside the compounded line. Every plan is stated to include free shipping, unlimited physician messaging, personalized protocols with meal plans and coaching, and third-party lab testing. It is cash-pay, accepts HSA/FSA cards and offers Klarna.

Asynchronous and program-priced, and thin on identity. You complete a health intake, connect with a licensed provider, and eligible patients receive medication shipped to the door; you are billed only after approval, refills process automatically, and you can pause or cancel the subscription at any time. Its quality claim is the notable one: medications are stated to be lab-tested for potency, sterility, pH and endotoxin. Those four are exactly what an injectable batch should be screened for, and naming them individually is meaningfully better than the vague "third-party tested" language most competitors use. It displays a LegitScript badge linked to the public checker. What is missing is names: the compounding pharmacies are described only as FDA-registered, US-based facilities and are never named, and clinicians are described as licensed and board-certified with no names, credentials or NPI numbers published. No state list is published either. Several molecules come in more than one route — sermorelin as injection or orally disintegrating tablet, NAD⁺ and glutathione as injection or nasal spray — a genuine convenience, though the alternative routes generally have weaker pharmacokinetic support than the injection.

Every product carries a monthly and a quarterly price, each split into a discounted first month and a higher ongoing rate. Sermorelin (a 10 mg vial, or the tablet version) is $195 for the first month and $225 a month after that on monthly billing, or $155 and then $185 a month on a quarterly plan. NAD⁺ in a 500 mg vial, or the nasal spray, is $170 then $190 a month on monthly billing, or $130 then $150 on quarterly; the 1,000 mg vial is $220 then $240, or $180 then $200. Glutathione (a 2,000 mg vial or the nasal spray) is $154 then $169, or $124 then $139. The site's footnote states that the quarterly prices apply to plans paid up front, and the headline "from" figure on every product is the quarterly first month. A site-wide promo code takes a further $20 off. So the honest monthly cost of sermorelin is $185 prepaid quarterly or $225 month-to-month, and of NAD⁺ $150 or $190 for the 500 mg vial. Vial sizes are stated, but the dose each month is set by your provider.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. ReadyRx states its medications are lab-tested for potency, sterility, pH and endotoxin, and that its pharmacies are FDA-registered, US-based compounding facilities, though it names none; compounded sterile products are not reviewed by the FDA for purity and potency the way approved drugs are. On the evidence, the menu spreads across tiers. Sermorelin is a GHRH analog stimulating your own pituitary — a real, well-described mechanism with thin long-term human outcome data, and the orally disintegrating tablet route has less pharmacokinetic support than the injection. NAD⁺ is sold here as an injection and as a nasal spray, and neither route has controlled human outcome trials; intranasal NAD⁺ in particular has very little pharmacokinetic characterization, while the NAD⁺ forms with human trial data are the oral precursors NR and NMN, which raise a blood level rather than demonstrate a benefit. Glutathione, injected or intranasal, has essentially no controlled human outcome data. Metformin is the outlier: an approved drug with decades of trial data for glycemic control, sold in this context on longevity claims that its own dedicated trial has not yet answered. Individual results vary.